CRO sector fluctuates weakly, and Zhao Yan's new drug hits the limit.

The CRO sector fluctuated weaker, with Zhaoyan Pharmaceuticals hitting the limit down, while Puress, Yinosi, Nuosige, Medis, Chengda Pharmaceuticals, Hait Biotech, and others followed with declines.